An injection of stem cells into the eye may soon slow or reverse the effects of early-stage age-related macular degeneration, according to new research from scientists at Cedars-Sinai
Currently, there is no treatment that slows the progression of the disease, which is the leading cause of vision loss in people over 65.
“This is the first study to show preservation of vision after a single injection of adult-derived human cells into a rat model with age-related macular degeneration,” said Shaomei Wang, MD, PhD, lead author of the study published in the journal STEM CELLS and a research scientist in the Eye Program at the Cedars-Sinai Board of Governors Regenerative Medicine Institute.
The stem cell injection resulted in 130 days of preserved vision in laboratory rats, which roughly equates to 16 years in humans.
Age-related macular degeneration affects upward of 15 million Americans. It occurs when the small central portion of the retina, known as the macula, deteriorates. The retina is the light-sensing nerve tissue at the back of the eye. Macular degeneration may also be caused by environmental factors, aging and a genetic predisposition.
When animal models with macular degeneration were injected with induced neural progenitor stem cells, which derive from the more commonly known induced pluripotent stem cells, healthy cells began to migrate around the retina and formed a protective layer. This protective layer prevented ongoing degeneration of the vital retinal cells responsible for vision.
Cedars-Sinai researchers in the Induced Pluripotent Stem Cell (iPSC) Core, directed by Dhruv Sareen, PhD, with support from the David and Janet Polak Foundation Stem Cell Core Laboratory, first converted adult human skin cells into powerful induced pluripotent stem cells (iPSC), which can be expanded indefinitely and then made into any cell of the human body. In this study, these induced pluripotent stem cells were then directed toward a neural progenitor cell fate, known as induced neural progenitor stem cells, or iNPCs.
“These induced neural progenitor stem cells are a novel source of adult-derived cells which should have powerful effects on slowing down vision loss associated with macular degeneration,” said Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute and contributing author to the study. “Though additional pre-clinical data is needed, our institute is close to a time when we can offer adult stem cells as a promising source for personalized therapies for this and other human diseases.”
Read more: Stem Cell Injection May Soon Reverse Vision Loss Caused By Age-Related Macular Degeneration
The Latest on: Age-Related Macular Degeneration
[google_news title=”” keyword=”Age-Related Macular Degeneration” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Age-Related Macular Degeneration
- 12 Health Benefits of Zinc for Women, According to Nutrition Expertson May 2, 2024 at 6:46 am
It is good for your skin. The antioxidant activity of zinc may be why it’s beneficial to skin health. “Zinc’s antioxidant properties help protect cells from damage caused by free radicals and helps ...
- Scientists identify new treatment target for leading cause of blindnesson May 2, 2024 at 6:08 am
Medical College of Georgia scientists report that a gene previously implicated in the development of atherosclerotic lesions in coronary arteries could be key to understanding why many people don't ...
- Astellas Pharma gets grant for novel carbocyclic prolinamide derivatives for treating age-related macular degenerationon May 2, 2024 at 6:05 am
Discover Astellas Pharma's patented carbocyclic prolinamide derivatives for treating eye diseases like macular degeneration. Explore the unique compound structure and potential applications in ...
- Scientists find potential treatment target for leading cause of blindnesson May 2, 2024 at 5:46 am
US scientists have found answers to why treatment for neovascular age-related macular degeneration (AMD) -- a leading cause of blindness -- does not benefit all; and also developed a potential ...
- Luxa Biotechnology Awarded $4 Million CIRM Grant to Support Clinical Trial of Adult RPESC-RPE-4W Therapy for Dry Age-related Macular Degenerationon May 1, 2024 at 4:00 am
Luxa Biotechnology (LuxaBio), a joint venture between Y2 Solution Co. Ltd, Seoul, South Korea and the Neural Stem Cell Institute (NSCI) in Rensselaer, New York, today announced receipt of a $4 million ...
- Lighthouse Guild Receives Grant from American Macular Degeneration Foundation (AMDF)on April 30, 2024 at 3:30 am
This number is expected to double by 2050, particularly due to age-related vision diseases like macular degeneration. While numerous assistive technology devices are now available, many people with ...
- Here’s How To Avoid These 3 Types of Age-Related Vision Losson April 29, 2024 at 6:30 am
Advanced age is a risk factor for blindness, but there’s a lot you can do to protect your vision before it’s too late.
- Local group helps macular degeneration patients cope with vision losson April 26, 2024 at 3:07 am
To provide opportunity for encouragement, Phoenix-based Associated Retina Consultants, in coordination with the International Low Vision Support Group, has established a Macular Degeneration Support ...
- High dose aflibercept may be promising for treatment of age-related macular degenerationon April 24, 2024 at 2:55 pm
Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks. 2. Ocular adverse events were comparable across treatment groups. Evidence Rating Level: 1 (Excellent) Study ...
- Dry Age-related Macular Degeneration Seven Major Market to Exhibit Growth at a CAGR of 19.8% by 2034 | DelveInsighton April 22, 2024 at 2:31 pm
DelveInsight's Dry Age-related Macular Degeneration Market Insights report includes a comprehensive understanding of current treatment practices, dry age-related macular degeneration marketed drug, ...
via Bing News